Former FDA chiefs turn criticism toward HHS leadership at STAT Summit
Three former FDA commissioners — Robert Califf, Scott Gottlieb, and Norman Sharpless — used the STAT Summit stage to aim sharp criticism at current HHS leadership. Their comments landed in a moment when the agency’s credibility, staffing stability, and policy direction sit at the center of nearly every drug, device, and biotech question in Washington.
The critique matters because the FDA does not operate in a vacuum. Its decisions shape whether new therapies reach patients on time, how quickly companies can plan trials, and how much confidence clinicians place in the regulatory process that sits between laboratory promise and bedside use. When former commissioners publicly question the department overseeing the agency, they are really speaking to the durability of the system itself.
The newsletter framing placed the exchange inside the final day of STAT Summit, a venue built for exactly this kind of collision between policy, industry, and medicine. A session with three former commissioners carries unusual weight on its own; each has occupied the same institutional seat and understands how much of FDA performance depends on steady leadership, predictable procedure, and a clear line between science and politics.
A blunt warning ran through the event even without a detailed transcript on the page. Health policy rarely turns on one announcement or one speech. It turns on whether regulators can keep their footing long enough for sponsors, investigators, and patients to trust the next decision will resemble the last one.
Why FDA stability remains a market and patient-access issue
For drug developers, FDA leadership is not an abstract governance question. It affects the tempo of review meetings, the tone of agency guidance, and the degree to which companies can model risk around development timelines. Small changes in regulatory predictability can alter investment decisions, manufacturing plans, and whether a promising program survives long enough to produce usable data.
For patients, the same stability determines whether innovation reaches them as approved therapy, delayed therapy, or no therapy at all. In areas such as rare disease, oncology, and cystic fibrosis, time lost to bureaucratic drift can translate into delayed access to treatments that have already cleared years of clinical testing. That is why criticism from former commissioners resonates far beyond the policy class in Washington.
The presence of Califf, Gottlieb, and Sharpless also reflects how tightly the modern FDA is tied to public confidence. When former leaders step into the public square to challenge HHS direction, they are signaling that the problem is not a single statutory dispute. It is whether the broader health apparatus can maintain a coherent operating model while political demands keep shifting around it.
One sentence captures the stakes: regulatory turbulence slows medicine even when science is ready.
Biotech policy, China, and the pressure on U.S. drugmakers
The same STAT Summit agenda pointed to another force shaping the FDA discussion: competition with China and the pressure on U.S. drugmakers to protect innovation. Rep. Jake Auchincloss was slated to discuss how Congress should defend U.S. biotech against China and stabilize the FDA, a pairing that reflects how regulatory execution and industrial policy now move together.
That combination is not accidental. A strong FDA is part of U.S. competitiveness because the agency sits at the chokepoint where innovation either becomes an approved product or remains a development asset. If the regulatory environment becomes erratic, the downstream effects can include weaker domestic investment, slower trial startup, and greater incentive for capital to flow toward jurisdictions that appear more predictable.
The policy conversation also reaches beyond large companies. Smaller biotech firms often depend on a clean, interpretable FDA process to survive between financing rounds. When agency direction appears uncertain, those companies can lose access to capital faster than large pharmaceutical firms, which have more room to absorb administrative delays.
In that sense, criticism from former commissioners is not just an intra-Washington dispute. It is a warning about the connection between governance and whether a high-risk scientific ecosystem can keep producing therapies that matter to patients.
A summit built around health system friction, not just regulation
The newsletter page framed the summit around several separate health policy threads, including employer pressure on insurers, artificial intelligence, and a discussion of costly drugs. Even in that compressed lineup, the unifying theme was friction: how money, regulation, and innovation grind against one another across the health system.
One item stood out for its human scale. An executive saved by a cystic fibrosis breakthrough was set to search for solutions to expensive drugs alongside an expert in drug-pricing policy. That juxtaposition reflects a central tension in medicine: the therapies that transform survival are often the same therapies that strain family finances and payer budgets. The FDA may not set drug prices, but the approval process it runs determines which breakthroughs ever enter that pricing fight.
This is where the former commissioners’ criticism gains a sharper edge. If the agency loses credibility or efficiency, the consequences do not stop at the regulatory office. They ripple outward into research funding, patient access, and the willingness of investors to back the next wave of biomedical development.
The human cost of policy drift sits behind the headlines
The page also marked the death of STAT’s Helen Branswell, the paper’s noted infectious disease reporter, from complications of cancer. Her death is a reminder that policy debates unfold inside a profession built around illness, mortality, and the urgency of getting decisions right.
Health journalism often tracks conflict in institutional language, but the underlying question never changes: will the system deliver timely, reliable care when people need it? FDA leadership, HHS oversight, and the tone set by former commissioners all feed into that answer.
Without more detail from the on-page summary, the most durable takeaway is structural. Three former FDA commissioners publicly criticized the current HHS leadership at a major policy forum, and they did so at a time when biotech innovation, Chinese competition, and the stability of the agency remain tightly linked. The unresolved issue is whether that criticism will produce a course correction, or simply add one more warning to a regulatory system already under strain.